

Introducing Kardia 12L ECG System

The world's first AI-powered handheld 12-lead electrocardiogram (ECG) device to include a unique single-cable design.

FDA-cleared and powered by the advanced KAI™ 12L AI algorithm, the world's first AI that can detect life-threatening cardiac conditions, including heart attack, using a reduced leadset, Kardia 12L offers outstanding clinical efficiency that can give healthcare providers detailed and actionable insights into patient heart activity in a broad range of healthcare settings. Kardia 12L simplifies ECG recordings with AI that is substantially equivalent to state-of-the-art ECG analysis solutions. It assists healthcare providers in rapid disease detection, enhances patient experience, and expands access to accurate heart data, shifting the paradigm in cardiac care.



Table of Contents

Kardia 12L ECG System by the Numbers

Learn more about
what makes
Kardia 12L unique.

Kardia 12L ECG System Determinations

Access the full list of
FDA-cleared Kardia 12L
determinations.

Resources

Read more about
Kardia 12L and access
images and video for
your coverage needs.

Kardia 12L ECG System by the Numbers

1.75M
ECGs

Powered by data from 1.75M ECGs

Kardia 12L's AI algorithms were trained and validated on large and diverse ECG datasets.

Data from leading medical centers is representative of the demographic breakdown of patients with heart conditions.

35
FDA-Cleared
Determinations

35 FDA-cleared determinations

Kardia 12L can detect 14 arrhythmias and 21 morphologies by employing multiple deep neural network AI models.

This enables healthcare providers to identify patient conditions and connect them to appropriate care more quickly, potentially improving patient experience and overall outcomes.

Click [here](#) to view a full list of determinations.

0.3
Pounds

0.3 Pounds with cable

Kardia 12L is a fraction of the size of state-of-the-art ECG machines, which weigh anywhere from 5–15 pounds.

Its small size makes it significantly more portable and convenient to use, enabling rapid data acquisition in a wide variety of settings, including primary and urgent care offices, employer clinics and other under-resourced or rural venues.

50%
Fewer
Electrodes

50% fewer electrodes

Kardia 12L's powerful AI enables the use of just 5 electrodes, compared with the 10 used in state-of-the-art ECG analysis solutions.

The reduced leadset makes Kardia 12L simpler to use than state-of-the-art ECG analysis solutions, placing accurate heart data in reach of more healthcare providers.



Kardia 12L ECG System Determinations

Rhythm Determinations

Major Rhythm Types

- Normal Sinus Rhythm
- Sinus Rhythm
- Atrial Fibrillation
- Atrial Flutter
- Paced Rhythm
- Junctional Rhythm
- Bigeminy

Rhythm Modifiers

- 1st Degree AV Block
- High Degree AV Block (Including 2nd and 3rd Degree AV Blocks)
- Sinus Arrhythmia
- Marked Sinus Arrhythmia
- Marked Bradycardia (Sinus Rhythm, Brachycardia)
- Supraventricular Tachycardia
- Sinus Tachycardia (Sinus Rhythm, Tachycardia)
- PVCs

Morphological Determinations

Intraventricular Block

- Right Bundle Branch Block (RBBB)
- Left Bundle Branch Block (LBBB)
- Other Intraventricular Block

Hypertrophy

- Left Ventricular Hypertrophy (LVH)
- Right Ventricular Hypertrophy (RVH)

Atrial Enlargement

- Left Atrial Enlargement (LAE)
- Right Atrial Enlargement (RAE)

Old/Previous

Myocardial Infarction

- Anterior MI Old
- Inferior MI Old
- Lateral MI Old

Recent/Acute

Myocardial Infarction

- Anterior MI Acute
- Inferior MI Acute
- Lateral MI Acute

Ischemia

- Anterior Ischemia
- Inferior Ischemia
- Lateral Ischemia

Prolonged QT

Paced ECG

Other Morphological Defects

- Early Repolarization
- Wolff-Parkinson-White (WPW) Syndrome

Normal or Otherwise Normal

Interval Estimations

- PR Interval
- QRS Duration
- QT Interval
- Heart-Rate Corrected QT (QTcB, and QTcF)
- Heart Rate

The provisional automated ECG analysis should not be used for clinical action if it has not been reviewed by a healthcare professional qualified to independently interpret the ECG signal. The four synthesized chest leads are not intended for diagnostic use.

“Not only is KAI 12L the first FDA-cleared AI that can detect a heart attack on a reduced leadset, but it also returns determinations for our broadest range of conditions yet. Paired with our pocket-sized Kardia 12L ECG System, this offering is poised to disrupt traditional care pathways and represents a leap forward in cardiac care.”

PRIYA ABANI
CEO of AliveCor

About AliveCor

AliveCor, Inc., the leading provider of FDA-cleared personal electrocardiogram (ECG) technology, is transforming cardiology with its medical-grade AI solutions. AliveCor is committed to providing innovative devices and services that empower patients and physicians with personalized and actionable heart data. With more than 250 million ECGs recorded, the company's Kardia devices are the most clinically validated personal ECGs in the world and can remotely detect six of the most common heart arrhythmias in just 30 seconds.

The company's latest offering, Kardia 12L ECG System, powered by KAI 12L to detect 35 cardiac conditions (14 arrhythmias and 21 morphologies), was designed exclusively for use by healthcare providers.

AliveCor's enterprise platform allows third-party providers to manage their patients' and customers' heart conditions simply using state-of-the-art tools that provide easy front-end and back-end integration to AliveCor technologies, addressing gaps in care and improving the treatment experience for patients across a range of disease areas.

AliveCor is a privately held company headquartered in Mountain View, California. For more information, visit [alivecor.com](https://www.alivecor.com) and follow us on [LinkedIn](#), [X](#), [Instagram](#) and [Facebook](#).



Resources

[AliveCor press release](#)

[Demo video](#)

[Learn more](#)